JAKARTA, May 22 (Xinhua) -- Indonesia's largest pharmaceutical company, PT Kalbe Farma, has set a target of 8 to 10 percent annual growth in net sales and net profit for 2025.
"With strong fundamentals and by leveraging opportunities from healthcare sector reforms through various business initiatives, we remain optimistic about continuing our growth amid a still challenging market environment," said Bernadette Ruth Irawati Setiady, president director of Kalbe Farma, on Thursday.
To support this target, Kalbe Farma has allocated a maximum capital expenditure of 1 trillion rupiah (61.2 million U.S. dollars) for the year. The company also plans a share buyback worth 250 billion rupiah to help stabilize its stock price amid market uncertainty.
Kalbe Farma approved a cash dividend distribution of 1.7 trillion rupiah, or 36 rupiah per share, equivalent to 52 percent of its net income for fiscal year 2024.
Established in 1966, Kalbe Farma is now one of Southeast Asia's leading integrated pharmaceutical firms, operating more than 40 subsidiaries and employing around 16,000 people. (1 U.S. dollar equals about 16,332 rupiah) ■
